Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023256 | 0.85 | USP2 (0.46) | USP2ALDH1A1CNR1CNR2DNM1 | |
| SCHEMBL19682026 | 0.82 | MGAM (0.38) | USP2ALDH1A1CNR1CNR2DNM1 | |
| SCHEMBL19682107 | 0.82 | MGAM (0.38) | USP2ALDH1A1CNR1CNR2DNM1 | |
| SCHEMBL19682032 | 0.82 | MGAM (0.38) | USP2ALDH1A1CNR1CNR2DNM1 | |
| SCHEMBL19682119 | 0.82 | MGAM (0.38) | USP2ALDH1A1CNR1CNR2DNM1 | |
| SCHEMBL5342645 | 0.82 | USP2 (0.43) | USP2ALDH1A1CNR1CNR2DNM1 | |
| SCHEMBL28027780 | 0.81 | DNM1 (0.42) | USP2DNM1HTTSPHK1LPAR6 | |
| SCHEMBL19682021 | 0.80 | MGAM (0.37) | USP2ALDH1A1CNR1CNR2DNM1 | |
| SCHEMBL20788856 | 0.79 | USP2 (0.50) | USP2ALDH1A1CNR1CNR2DNM1 | |
| SCHEMBL20788836 | 0.79 | USP2 (0.50) | USP2ALDH1A1CNR1CNR2DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382574-A1 | METHODS AND COMPOSITIONS FOR ORALLY DOSING ANIMALS | Animal Science Products, Inc. (US) | 2024-11-21 | — | — | US | disclosed |
| CN-111499698-B | Canine I type adenovirus subunit vaccine and preparation method thereof | 中国农业科学院特产研究所 | 2023-05-16 | — | — | CN | disclosed |
| EP-2900678-B1 | MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG | CENTRE NAT RECH SCIENT (FR) | 2020-09-02 | — | — | EP | disclosed |
| US-10632135-B2 | Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-04-28 | — | — | US | disclosed |
| US-10273313-B2 | Multimeric mannosides, a process for preparing the same and their uses as a drug | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-04-30 | — | — | US | disclosed |
| US-9750797-B2 | Sustained release vaccine composition | VIRBAC CORPORATION (US) | 2017-09-05 | — | — | US | disclosed |
| EP-3096747-A1 | ORALLY AVAILABLE COMPOUNDS, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS ANTI-ADHESIVE DRUGS FOR TREATING E. COLI INDUCED INFLAMMATORY BOWEL DISEASES SUCH AS CROHN'S DISEASE | Centre National De La Recherche Scientifique (FR) | 2016-11-30 | — | — | EP | disclosed |
| US-20160340445-A1 | ORALLY AVAILABLE COMPOUNDS, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS ANTI-ADHESIVE DRUGS FOR TREATING E. COLI INDUCED INFLAMMATORY BOWEL DISEASES SUCH AS CROHN'S DISEASE | NANTES UNIVERSITE (FR) | 2016-11-24 | — | — | US | disclosed |
| EP-2900678-A1 | MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG | Centre National de la Recherche Scientifique (C.N.R.S.) (FR) | 2015-08-05 | — | — | EP | disclosed |
| US-20150210781-A1 | MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG | NANTES UNIVERSITE (FR) | 2015-07-30 | — | — | US | disclosed |
| WO-2015110609-A1 | ORALLY AVAILABLE COMPOUNDS, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS ANTI-ADHESIVE DRUGS FOR TREATING E. COLI INDUCED INFLAMMATORY BOWEL DISEASES SUCH AS CROHN'S DISEASE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-07-30 | — | — | WO | disclosed |
| WO-2014016361-A1 | MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-01-30 | — | — | WO | disclosed |
| EP-2690105-A1 | Mannose derivatives, a process for preparing the same and their uses as a drug | Centre National De La Recherche Scientifique (FR) | 2014-01-29 | — | — | EP | disclosed |
| CN-101316610-A | Immunogenic fragments of T cell receptor constant regions and peptides derived therefrom | COHEN IRUN R (IL) | 2008-12-03 | — | — | CN | disclosed |
| EP-1765385-A4 | SUSTAINED RELEASE VACCINE COMPOSITION | SMART DRUG SYSTEMS INC (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080199491-A1 | Sustained Release Vaccine Composition | VIRBAC CORPORATION | 2008-08-21 | — | — | US | disclosed |
| EP-1765385-A1 | SUSTAINED RELEASE VACCINE COMPOSITION | Smart Drug Systems Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123120-A1 | SUSTAINED RELEASE VACCINE COMPOSITION | SMART DRUG SYSTEMS INC. (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273313-B2 | Multimeric mannosides, a process for preparing the same and their uses as a drug | MANBA, MAN2A1, MAN2B2 | USP2 2525/4885ALDH1A1 2762/4885CNR1 2580/4885 |
| US-10632135-B2 | Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease | ICAM1, VCAM1, EPCAM | USP2 3428/4885ALDH1A1 1695/4885CNR1 3320/4885 |
| US-20160340445-A1 | ORALLY AVAILABLE COMPOUNDS, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS ANTI-ADHESIVE DRUGS FOR TREATING E. COLI INDUCED INFLAMMATORY BOWEL DISEASES SUCH AS CROHN'S DISEASE | ICAM1, VCAM1, EPCAM | USP2 3428/4885ALDH1A1 1695/4885CNR1 3320/4885 |
| US-20150210781-A1 | MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG | MANBA, MAN2A1, MAN2B2 | USP2 2525/4885ALDH1A1 2762/4885CNR1 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.